SMF                                             pancreas(124,125)
 _________________________________________________________________
  streptozotocin.. 1,000 mg/sqm IV on days 1, 8, 29, and 35.
  mitomycin....... 10 mg/sqm IV day 1.
  fluorouracil.... 600 mg/sqm IV on days 1, 8, 29, and 35.
  FREQUENCY....... Repeat cycle every 56 days.

  reference...
    Wiggans RG.  Woolley PV.  Macdonald JS.  Smythe T.  Ueno W. 
    Schein PS. Phase II trial of streptozotocin, mitomycin-C and 
    5-fluorouracil (SMF) in the treatment of advanced pancreatic 
    cancer. Cancer.  41(2):387-91, 1978 Feb. 
  abstract...
    Ten of 23 patients with advanced measureable adenocarcinoma of 
    the pancreas achieved an objective response after treatment 
    with a regimen consisting of streptozotocin, mitomycin-C and 
    5-fluorouracil (SMF). The median duration of response is in 
    excess of 7 months and responding patients have lived 
    significantly longer than patients with progressive disease 
    (7.5 + months vs. 3 months). The SMF regimen was adequately 
    tolerated. Principal toxicities included myelosuppression, 
    which was generally mild, nausea and vomiting. There was 
    reversible nephrotoxicity in the form of proteinuria in 30% of 
    patients and persistent axotemia in 9% of patients. 

  reference...
    Oster MW.  Gray R.  Panasci L.  Perry MC. Chemotherapy for 
    advanced pancreatic cancer. A comparison of 5-fluorouracil, 
    adriamycin, and mitomycin (FAM) with 5-fluorouracil, 
    streptozotocin, and mitomycin (FSM). Cancer.  57(1):29-33, 
    1986 Jan 1. 
  abstract...
    One hundred ninety-six patients with advanced pancreatic 
    cancer were randomized to receive one of two combination 
    chemotherapy programs: FAM (5-fluorouracil, Adriamycin 
    [doxorubicin], mitomycin) or FSM (5-fluorouracil, 
    streptozotocin, mitomycin). Patient characteristics were 
    comparable in both groups. Overall response rates for those 
    with measurable disease (14% on FAM, 4% on FSM) were not 
    significantly different (P = 0.07). There was no significant 
    difference in overall survival between patients treated with 
    FAM and FSM (median survivals of 26 and 18 weeks, 
    respectively). Survival benefits of FAM were significant only 
    for patients with measurable disease. Toxicity of both 
    regimens was acceptable and comparable, aside from greater 
    renal toxicity and more nausea and vomiting with FSM. The 
    results failed to confirm the 35% to 40% response rates 
    previously reported for FAM and FSM in advanced pancreatic 
    cancer.